TriangleNCT00866281 · OUTCOME
Overall Survival With Midostaurin
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
What was measured
Overall survival (OS) was defined as the time from start of treatment to date of death due to any cause. The percentage (%) event-free probability estimates were obtained from the Kaplan-Meier survival estimates.
Analysis population: The analysis was performed in FAS population.
Groups in this outcome
AML Subjects
Subjects with acute myeloid leukemia (AML) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\^2.
MLLr-ALL Subjects
Subjects with mixed lineage leukemia gene- rearranged acute lymphoblastic leukemia (MLLr-ALL) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\^2.
| Group | Source count |
|---|---|
| AML Subjects | 9 |
| MLLr-ALL Subjects | 13 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| AML Subjects | 3.68 | Not reported | 2.727 | 8.312 | Not reported |
| MLLr-ALL Subjects | 1.35 | Not reported | 0.953 | 2.924 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.727
- upper Limit
- 8.312
- value
- 3.68
- group Id
- OG001
- lower Limit
- 0.953
- upper Limit
- 2.924
- value
- 1.35
- denoms
- counts
- group Id
- OG000
- value
- 9
- group Id
- OG001
- value
- 13
- units
- Participants
- description
- Overall survival (OS) was defined as the time from start of treatment to date of death due to any cause. The percentage (%) event-free probability estimates were obtained from the Kaplan-Meier survival estimates.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Subjects with acute myeloid leukemia (AML) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\^2.
- id
- OG000
- title
- AML Subjects
- description
- Subjects with mixed lineage leukemia gene- rearranged acute lymphoblastic leukemia (MLLr-ALL) and received body-weight stratified dosage midostaurin 30 or 60 mg/m\^2.
- id
- OG001
- title
- MLLr-ALL Subjects
- param Type
- MEDIAN
- population Description
- The analysis was performed in FAS population.
- reporting Status
- POSTED
- time Frame
- Baseline, End of treatment (up to 24 months after last dose or until death whichever occurred first)
- title
- Overall Survival With Midostaurin
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice